Epinephrine Dose: Optimal Versus Standard Evaluation Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1250 participants.
Also called NCT03826524
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,250 participants
- Registry
-
NCT03826524
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT03826524. Randomized; triple masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Epinephrine Dose: Optimal Versus Standard Evaluation Trial
- Acronym
- EpiDOSE
- Condition
- Cardiac Arrest, Out-Of-Hospital
- Condition
- Sudden Cardiac Arrest
- Condition
- Ventricular Fibrillation
- Condition
- Ventricular Tachycardia-Pulseless
- Intervention (Drug)
- Epinephrine
- Lead sponsor
- Unity Health Toronto
- Collaborator
- Canadian Institutes of Health Research (CIHR)
Record details
- Record id
cardio:ct-nct03826524- Content hash
ae2d73f6be7b52faf448b4975ed054e7d5008bd7283690fc0f92a3ff679d7b86